The effects of progesterone receptor blockade in the luteal phase of normal fertile women.
The effects of a single, variable dose (5 to 200 mg) of RU38486 (RU486) (Roussel-Uclaf, Paris, France) in the first half of the luteal phase of the menstrual cycle were studied in 30 normal fertile volunteers. Quantitative histologic techniques were employed, and the results were compared with normal ranges derived from a separate, normal, fertile population. It was found that RU486 inhibited glandular secretory activity, accelerated degenerative changes, induced various vascular changes, increased stromal but not glandular mitotic activity, and did not affect the predecidual reaction. The superiority of morphometric analysis over traditional dating criteria was demonstrated in this study of endometrial responses to an exogenously administered agent. In addition, it was found that temperature drop occurred in 56%, menstrual induction in 43%, luteolysis in 24%, mood change in 23%, and thirst sensation in 3% of women studied. Both menstrual induction and changes in hypothalamic function after the administration of RU486 occurred independently of luteolysis and so were likely to be the direct result of progesterone receptor blockade in these organs. Menstrual induction was significantly related to the dose given and the day on which RU486 was administered. Mood change was significantly related to the day on which RU486 was given. Most of the effects of RU486 occurred around 48 hours after its administration.
Li
T C
TC
University of Sheffield, Jessop Hospital for Women, England.
Dockery
P
P
Thomas
P
P
Rogers
A W
AW
Lenton
E A
EA
Cooke
I D
ID
D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D001833:Body Temperature Regulation / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D008183:Luteal Phase / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000187:drug effects; D015735:Mifepristone; D008938:Mitosis / Q000187:drug effects; D011374:Progesterone / Q000032:analysis; D011372:Progestins / Q000037:antagonists & inhibitors*; D011980:Receptors, Progesterone / Q000187:drug effects*; D012463:Saliva / Q000032:analysis
D004963:Estrenes; D011372:Progestins; D011980:Receptors, Progesterone; D015735:Mifepristone; D011374:Progesterone; D007986:Luteinizing Hormone